401 related articles for article (PubMed ID: 17459681)
1. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
2. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Horsman MR; Bohn AB; Busk M
Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
[TBL] [Abstract][Full Text] [Related]
3. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
4. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and vascular targeting: relevance for hyperthermia.
Horsman MR
Int J Hyperthermia; 2008 Feb; 24(1):57-65. PubMed ID: 18214769
[TBL] [Abstract][Full Text] [Related]
6. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
7. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
Wachsberger P; Burd R; Dicker AP
Clin Cancer Res; 2003 Jun; 9(6):1957-71. PubMed ID: 12796357
[TBL] [Abstract][Full Text] [Related]
8. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
10. Selective targeting of the tumour vasculature.
Chan LS; Daruwalla J; Christophi C
ANZ J Surg; 2008 Nov; 78(11):955-67. PubMed ID: 18959693
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
12. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
13. Taking down tumors: vascular disrupting agents entering clinical trials.
O'Hanlon LH
J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
[No Abstract] [Full Text] [Related]
14. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Horsman MR; Siemann DW
Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
[TBL] [Abstract][Full Text] [Related]
15. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
16. Optical imaging and tumor angiogenesis.
Lin PC
J Cell Biochem; 2003 Oct; 90(3):484-91. PubMed ID: 14523982
[TBL] [Abstract][Full Text] [Related]
17. Radiobiology and vascular targeting in glioma.
Short SC; Harney J
Curr Opin Neurol; 2003 Dec; 16(6):651-5. PubMed ID: 14624072
[TBL] [Abstract][Full Text] [Related]
18. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenics and radiotherapy.
Shannon AM; Williams KJ
J Pharm Pharmacol; 2008 Aug; 60(8):1029-36. PubMed ID: 18644195
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
Bouzin C; Feron O
Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
